Equillium (EQ) Revenue (2023 - 2024)
Equillium (EQ) posted quarterly Revenue of $4.4 million for Q4 2024, down 52.32% year-over-year from $9.2 million in Q1 2024, and down 63.88% quarter-over-quarter from $12.2 million in Q3 2024.
Powered by 
Analysis
Equillium (EQ) Revenue (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported Revenue for 2 consecutive years, with $4.4 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Revenue fell 52.32% year-over-year to $4.4 million; the TTM figure through Sep 2025 stood at $4.4 million (down 90.43% YoY), while the FY2024 annual figure was $41.1 million, up 13.89% from the prior year.
- Revenue eased to $4.4 million in Q4 2024 per EQ's latest filing, from $12.2 million in the prior quarter.
- Across five years, Revenue topped out at $13.9 million in Q2 2024 and bottomed at $4.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Equillium | 249.06 Mn | 249.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 12.16 Mn |
| Jun 30, 2024 | 13.85 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 9.21 Mn |
| Sep 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 9.12 Mn |
| Mar 31, 2023 | 8.88 Mn |